Emergent BioSolutions
Clinical trials sponsored by Emergent BioSolutions, explained in plain language.
A biopharmaceutical company specializing in vaccines and medical countermeasures.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Anthrax drug under the microscope: will it save lives? Results expected Jul 2027 (estimated)
- Emergency anthrax drug trial set to launch if outbreak strikes Results expected Jul 2027 (estimated)
- Can a blood product fix smallpox vaccine side effects? Results expected Aug 2027 (estimated)
-
New anthrax vaccine shows promise in large trial
Vaccine CompletedThis Phase 3 trial tested a new anthrax vaccine called AV7909 in nearly 3,700 healthy adults. The vaccine aims to protect people after they have been exposed to anthrax bacteria. Results showed that AV7909 produced a strong immune response and was safe, similar to the current lic…
Phase 3 • Sponsor: Emergent BioSolutions • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
-
New naloxone spray tested for faster overdose help
Knowledge-focused CompletedThis study tested a new device (AP003) that delivers naloxone as a nasal spray to reverse opioid overdoses. Twenty-four healthy adults received multiple doses to see how the drug moves through the body and to check for side effects. The goal was to compare the new spray with an e…
Phase 1 • Sponsor: Emergent BioSolutions • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Anthrax vaccine and antibiotics: a safety check
Knowledge-focused CompletedThis study looked at whether giving the anthrax vaccine AV7909 along with common antibiotics (ciprofloxacin or doxycycline) changes how the body processes those antibiotics. 210 healthy adults received the vaccine and antibiotics on a set schedule. The goal was to see if the vacc…
Phase 2 • Sponsor: Emergent BioSolutions • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:36 UTC